ResMed stock reports 10 percent fiscal revenue growth

ResMed stock was trading at USD 222.30 on Nasdaq on September 23, 2026, at 4:00 p.m. ET after hours, while fiscal 2026 revenue rose 10 percent to USD 5,653 million. The company also lifted its quarterly dividend 10 percent to USD 0.66 per share, with payment scheduled for September 24, 2026.

Revenue growth reaches 10 percent

According to Stock Titan, ResMed generated USD 5,653 million in fiscal 2026 revenue, up 10 percent from USD 5,146 million in fiscal 2025. GAAP diluted EPS increased to USD 10.43 from USD 9.51, while operating cash flow reached USD 1,806 million.

The earnings mix shows why operating quality matters alongside sales growth. Fiscal 2026 operating margin was 33.4 percent, and non-GAAP operating margin was 36.1 percent, giving the company a sizable earnings contribution beyond the top-line increase.

RBC raises its price objective

As MarketBeat reports, Royal Bank of Canada upgraded ResMed from Sector Perform to Outperform and raised its price objective from USD 244.00 to USD 262.00 in a September 15, 2026 research note. The same report lists a consensus Hold rating and an average target of USD 241.69.

That target sits above the September 23 quote, but the market snapshot remains below the yearly peak. The combination of double-digit fiscal revenue growth and a target revision gives investors two concrete markers for assessing whether earnings execution can narrow the valuation gap.

The stock sits below its yearly high

ResMed stock was trading at USD 222.30 on Nasdaq on September 23, 2026, at 4:00 p.m. ET after hours. The price stood 21.96 percent below the 52-week high of USD 284.87 and above the 52-week low of USD 180.27.